
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Increased use of mobile technologies such as smartphones is spurring growing acceptance of - and reliance on - dermatology apps. Currently available applications for dermatologists provide reference tools (i.e. textbooks), and a few provide decision support based on information that a dermatologist enters into the application.






